Ardelyx Stock Forecast, Price & News

Ardelyx's stock was trading at $5.98 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ARDX shares have decreased by 0.3% and is now trading at $5.96.
View which stocks have been most impacted by COVID-19.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Ardelyx.

Wall Street analysts have given Ardelyx a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Ardelyx wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Ardelyx is scheduled to release its next quarterly earnings announcement on Friday, March 5th 2021.
View our earnings forecast for Ardelyx.

Ardelyx, Inc. (NASDAQ:ARDX) released its quarterly earnings data on Tuesday, November, 10th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.08. Ardelyx had a negative return on equity of 53.93% and a negative net margin of 1,063.74%.
View Ardelyx's earnings history.

3 equities research analysts have issued 12-month price targets for Ardelyx's stock. Their forecasts range from $11.00 to $13.00. On average, they expect Ardelyx's stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 101.3% from the stock's current price.
View analysts' price targets for Ardelyx.

Some companies that are related to Ardelyx include I-Mab (IMAB), uniQure (QURE), Kura Oncology (KURA), Intra-Cellular Therapies (ITCI), Viela Bio (VIE), Myovant Sciences (MYOV), IGM Biosciences (IGMS), Zentalis Pharmaceuticals (ZNTL), Ironwood Pharmaceuticals (IRWD), Prestige Consumer Healthcare (PBH), Y-mAbs Therapeutics (YMAB), Cryoport (CYRX), Generation Bio (GBIO), Amarin (AMRN) and Madrigal Pharmaceuticals (MDGL).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ardelyx investors own include Micron Technology (MU), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP), TherapeuticsMD (TXMD) and Advanced Micro Devices (AMD).

Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."

Ardelyx's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.57%), State Street Corp (3.01%), Pekin Hardy Strauss Inc. (1.91%), Pekin Hardy Strauss Inc. (1.91%), Assenagon Asset Management S.A. (0.75%) and Candriam Luxembourg S.C.A. (0.72%). Company insiders that own Ardelyx stock include David M Mott, David P Rosenbaum, Elizabeth A Grammer, Forest Baskett, Jeffrey W Jacobs, Justin A Renz, Mark Kaufmann, Michael Raab, Robert Blanks, Scott D Sandell and Susan Rodriguez.
View institutional ownership trends for Ardelyx.

ARDX stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, JPMorgan Chase & Co., BlackRock Inc., Teacher Retirement System of Texas, AQR Capital Management LLC, California State Teachers Retirement System, Jane Street Group LLC, and Alps Advisors Inc.. Company insiders that have sold Ardelyx company stock in the last year include Elizabeth A Grammer, Forest Baskett, Jeffrey W Jacobs, Justin A Renz, Michael Raab, Robert Blanks, Scott D Sandell, and Susan Rodriguez.
View insider buying and selling activity for Ardelyx.

ARDX stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Candriam Luxembourg S.C.A., Pekin Hardy Strauss Inc., Pekin Hardy Strauss Inc., Point72 Asset Management L.P., Cubist Systematic Strategies LLC, Boothbay Fund Management LLC, and BNP Paribas Arbitrage SA.
View insider buying and selling activity for Ardelyx.

Shares of ARDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ARDX stock can currently be purchased for approximately $5.96.

Ardelyx has a market capitalization of $537.88 million and generates $5.28 million in revenue each year. The biopharmaceutical company earns $-94,940,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis. Ardelyx employs 88 workers across the globe.

The official website for Ardelyx is www.ardelyx.com.

Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The biopharmaceutical company can be reached via phone at 510-745-1700 or via email at [email protected]